![David T. Shima](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dr. David T.
Shima is Chief Scientific Officer at Ophthotech Corp.
Dr. Shima was previously employed as Chief Scientific Officer-Ophthalmology by ThromboGenics NV.
He received his undergraduate degree from The Ohio State University and a doctorate degree from Harvard University.
| Sociétés | Poste | Fin |
|---|---|---|
| IVERIC BIO, INC. | Directeur Technique/Scientifique/R&D | - |
| OXURION NV | Directeur Technique/Scientifique/R&D | 16/01/2013 |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 4 |
|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Ohio State University
 The Ohio State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oxurion NV
 Oxurion NV Pharmaceuticals: MajorHealth Technology Develops innovative vascular biopharmaceuticals for the treatment of eye disease, vascular disease and cancer | Health Technology |
IVERIC bio, Inc.
 IVERIC bio, Inc. BiotechnologyHealth Technology Operates as a science-driven biopharmaceutical company that develops novel treatments for retinal diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
Choisissez Zonebourse 
